Show simple item record

dc.contributor.authorSvistunov A.A.
dc.contributor.authorTarasov V.V.
dc.contributor.authorShakhmardanova S.A.
dc.contributor.authorSologova S.S.
dc.contributor.authorBagaturiya E.T.
dc.contributor.authorChubarev V.N.
dc.contributor.authorGalenko-Yaroshevsky P.A.
dc.contributor.authorÁvila-Rodriguez M.F.
dc.contributor.authorBarreto G.E.
dc.contributor.authorAliev G.
dc.date.accessioned2020-09-02T22:28:49Z
dc.date.available2020-09-02T22:28:49Z
dc.date.issued2018
dc.identifier10.2174/1389203718666170829162335
dc.identifier.citation19, 9, 924-934
dc.identifier.issn13892037
dc.identifier.urihttps://hdl.handle.net/20.500.12728/6355
dc.descriptionUrotensin II (UT II) is an important factor of cellular homeostasis. This regulatory peptide is involved in the pathophysiology of many disorders. For example, it plays an important role in the pathogenesis of acute and chronic diseases, stressful and adaptive reactions of the body, in the development of cardiovascular pathologies, metabolic syndrome, inflammation, liver cirrhosis, renal failure, diabetic nephropathy, reproductive dysfunction, progression of psychosomatic, psychoendocrinal and psychiatric disorders. In this concern, the involvement of UT II in the pathophysiology of many processes determines the perspectives for the development of blockers of urotensin receptors for the treatment of the aforementioned diseases. It is important that even today this kind of perspective is feasible due to the synthesis of a series of GPR14 blockers. The objective of this review is to discuss current molecular mechanisms of biological activity, regulatory functions of UT II, its role in the pathogenesis of different nosologies, as well as analysis of the possible routes of exposure to GPR14 as potential therapeutic targets. © 2018 Bentham Science Publishers.
dc.language.isoen
dc.publisherBentham Science Publishers B.V.
dc.subjectCancer
dc.subjectDrug design
dc.subjectG-protein-coupled receptors
dc.subjectHormonal systems
dc.subjectKidney
dc.subjectMolecular targets of Urotensin II in cardiovascular
dc.subjectNervous
dc.subjectRegulatory peptides
dc.subjectSexual function
dc.subjectStress
dc.subjectUrotensin II
dc.subjectG protein coupled receptor
dc.subjecturotensin
dc.subjecturotensin II
dc.subjectUTS2R protein, human
dc.subjectanimal
dc.subjectantagonists and inhibitors
dc.subjectatherosclerosis
dc.subjectdiabetes mellitus
dc.subjectheart failure
dc.subjecthomeostasis
dc.subjecthuman
dc.subjecthypertension
dc.subjectkidney failure
dc.subjectmetabolism
dc.subjectmolecularly targeted therapy
dc.subjectAnimals
dc.subjectAtherosclerosis
dc.subjectDiabetes Mellitus
dc.subjectDrug Therapy
dc.subjectHeart Failure
dc.subjectHomeostasis
dc.subjectHumans
dc.subjectHypertension
dc.subjectMolecular Targeted Therapy
dc.subjectReceptors, G-Protein-Coupled
dc.subjectRenal Insufficiency
dc.subjectUrotensins
dc.titleUrotensin II: Molecular mechanisms of biological activity
dc.typeReview


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record